Patheon Acquires IRIX Pharmaceuticals
Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.
Patheon announced on March 4 that it has reached a definitive agreement to acquire Florence, SC-based IRIX Pharmaceuticals, which specializes in difficult-to-manufacture APIs for drugs from early and late development, through commercial launch. Patheon will purchase IRIX and expects to close the transaction in 60 days.
Patheon reports that with the acquisition, it secures additional API development and manufacturing services in the United States, including high-potency (SafeBridge Class IV-certified) and controlled substances (Schedule 1-4). IRIX has facilities for the optimization of chemical processes and scale up for commercial API manufacturing in Florence and Greenville, SC.
The combined companies will offer an array of process technologies, including biocatalysis, homogeneous catalysis, and microreactors and are positioned to address a range of supply chain issues for customers, according to a press statement.
Source: Patheon
